Compare WKC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WKC | IOVA |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 2008 |
| Metric | WKC | IOVA |
|---|---|---|
| Price | $35.40 | $8.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $28.00 | $9.00 |
| AVG Volume (30 Days) | 838.5K | ★ 17.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $36,916,600,000.00 | N/A |
| Revenue This Year | $0.62 | $47.74 |
| Revenue Next Year | $3.42 | $40.31 |
| P/E Ratio | $24.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.21 | $1.76 |
| 52 Week High | $41.20 | $9.36 |
| Indicator | WKC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 68.70 |
| Support Level | $22.77 | $3.57 |
| Resistance Level | $37.88 | $9.36 |
| Average True Range (ATR) | 0.87 | 0.58 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 10.53 | 74.12 |
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.